Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: retroviral replicating vector based cancer immunotherapy - Forte Biosciences

Next Previous
Drug Profile

Research programme: retroviral replicating vector based cancer immunotherapy - Forte Biosciences

Alternative Names: RRV-NAO; Toca 521; Toca RNAi

Latest Information Update: 31 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Southern California
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 27 Aug 2026 Forte Biosciences has been acquired by argenx
  • 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer in USA
  • 28 Apr 2020 Denovo Biopharma plans to acquire Tocagen's retroviral replicating vector platform, its investigational gene therapy and drug regimen for oncology after completion of Tocagen's anticipated merger with Forte Biosciences

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top